Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice

European Journal of Cardio-thoracic Surgery

Volumn 32, Issue 4, 2007, Pages 577-581

  Shime, Nobuaki ^a   Kato, Yuko ^a   Kosaka, Tadashi ^a   Kokufu, Takatoshi ^a   Yamagishi, Masaaki ^a   Fujita, Naohisa ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antimicrobial prophylaxis; Cardiopulmonary bypass; Paediatric cardiac surgery; Teicoplanin; Vancomycin

Indexed keywords

PSEUDOMONIC ACID; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COST; DRUG SAFETY; FEMALE; HEART SURGERY; HEMODIAFILTRATION; HIGH RISK POPULATION; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONEY; PEDIATRIC SURGERY; POSTOPERATIVE INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CARDIOPULMONARY BYPASS; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; METHICILLIN RESISTANCE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; TREATMENT OUTCOME; VANCOMYCIN;

EID: 34548428271     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.07.008     Document Type: Article

References (25)

1. Zanetti G., Goldie S.J., and Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 7 (2001) 820-827
2. Edwards F.H., Engelman R.M., Houck P., Shahian D.M., and Bridges C.R. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg 81 (2006) 397-404
3. Garey K.W., Dao T., Chen H., Amrutkar P., Kumar N., Reiter M., and Gentry L.O. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother 58 (2006) 645-650
4. Hatzopoulos F.K., Stile-Calligaro I.L., Rodvold K.A., Sullivan-Bolyai J., Del Nido P., and Levitsky S. Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. Pediatr Infect Dis J 12 (1993) 300-304
5. Allpress A.L., Rosenthal G.L., Goodrich K.M., Lupinetti F.M., and Zerr D.M. Risk factors for surgical site infections after pediatric cardiovascular surgery. Pediatr Infect Dis J 23 (2004) 231-234
6. Levy I., Ovadia B., Erez E., Rinat S., Ashkenazi S., Birk E., Konisberger H., Vidne B., and Dagan O. Nosocomial infections after cardiac surgery in infants and children: incidence and risk factors. J Hosp Infect 53 (2003) 111-116
7. Begg E.J., Barclay M.L., and Kirkpatrick C.J. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 47 (1999) 23-30
8. Freeman C.D., Quintiliani R., and Nightingale C.H. Vancomycin therapeutic drug monitoring: is it necessary?. Ann Pharmacother 27 (1993) 594-598
9. Ortega G.M., Marti-Bonmati E., Guevara S.J., and Gomez I.G. Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass inpatients undergoing cardiac surgery. Am J Health Syst Pharm 1 60 (2003) 260-265
10. Kitzes-Cohen R., Farin D., Piva G., Ivry S., Sharony R., Amar R., and Uretzky G. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 22 (2000) 661-667
11. Miglioli P.A., Merlo F., Grabocka E., and Padrini R. Effects of cardio-pulmonary bypass on vancomycin plasma concentration decay. Pharmacol Res 38 (1998) 275-278
12. Vuorisalo S., Pokela R., and Syrjala H. Is single-dose antibiotic prophylaxis sufficient for coronary artery bypass surgery? An analysis of peri- and postoperative serum cefuroxime and vancomycin levels. J Hosp Infect 37 (1997) 237-247
13. Krivoy N., Yanovsky B., Kophit A., Zaher A., Bar-El Y., Adler Z., Gaitini L., and Milo S. Vancomycin sequestration during cardiopulmonary bypass surgery. J Infect 45 (2002) 90-95
14. Klamerus K.J., Rodvold K.A., Silverman N.A., and Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother 32 (1988) 631-635
15. Wilson A.P., Taylor B., Treasure T., Gruneberg R.N., Patton K., Felmingham D., and Sturridge M.F. Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin. J Antimicrob Chemother 21 (1988) 201-212
16. Wilson A.P., Shankar S., Felmingham D., Treasure T., and Gruneberg R.N. Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen. J Antimicrob Chemother 23 (1989) 613-617
17. Mini E., Mazzei T., Reali E.F., Novelli A., and Periti P. Pharmacokinetics of teicoplanin during cardiopulmonary bypass surgery. Int J Clin Pharmacol Res 9 (1989) 287-292
18. Miglioli P.A., Merlo F., Campanile F., and Padrini R. Effects of cardiopulmonary bypass on teicoplanin serum disposition. Int J Clin Pharmacol Res 15 (1995) 23-25
19. Martin C., Bourget P., Alaya M., Sertin A., Atlani C., Ennabli K., and Said R. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 41 (1997) 1150-1155
20. Miglioli P.A., Merlo F., Fabbri A., and Padrini R. Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery. J Antimicrob Chemother 39 (1997) 229-233
21. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs 7 (2006) 740-749
22. Dittrich S., Aktuerk D., Seitz S., Mehwald P., Schulte-Monting J., Schlensak C., and Kececioglu D. Effects of ultrafiltration and peritoneal dialysis on proinflammatory cytokines during cardiopulmonary bypass surgery in newborns and infants. Eur J Cardiothorac Surg 25 (2004) 935-940
23. Huang H., Yao T., Wang W., Zhu D., Zhang W., Chen H., and Fu W. Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg 76 (2003) 136-140
24. Nateghian A., Taylor G., and Robinson J.L. Risk factors for surgical site infections following open-heart surgery in a Canadian pediatric population. Am J Infect Control 32 (2004) 397-401
25. Mini E., Nobili S., and Periti P. Does surgical prophylaxis with teicoplanin constitute a therapeutic advance?. J Chemother 12 (2000) 40-55